Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada.
Sleep Med. 2012 Aug;13(7):893-7. doi: 10.1016/j.sleep.2011.12.014. Epub 2012 Jun 14.
According to published guidelines regarding the use of benzodiazepines or z-hypnotics (BZD-Z), the elderly should avoid hypnotic BZD, and use anxiolytic BZD and z-hypnotics only at low doses and for a short time. Our objective is to quantify inappropriate BZD-Z use in the elderly.
The study population consisted of people aged 70-89 who filled at least two prescriptions in 2008 within one of three subgroups: anxiolytic BZD, hypnotics BZD, or z-hypnotics. Inappropriate use criteria used for this study were (1) any hypnotic BZD, (2) exceeding 300 DDD, or a dosage exceeding 9 DDD/week, or anxiolytic BZD and z-hypnotics use exceeding 30 weeks.
118,526 persons, or 25% of elderly Norwegians, filled at least two prescriptions for one of these medication subgroups. Inappropriate use was found for 25% of anxiolytic BZD users, 100% of hypnotic BZD users, and 65% of z-hypnotic users. Altogether 57,276 elderly Norwegians, or 12.3% of the elderly source population, used BZD-Z inappropriately as defined in this study.
Clearly, inappropriate use of BZD-Z is widespread. An active response to such noncompliance with existing guidelines could consist of either (1) stricter enforcement of guidelines or (2) revamping guidelines through a fresh look at risks, benefits, and treatment practices. The implications of both options are discussed in some detail.
根据关于苯二氮䓬类药物或 Z 类催眠药(BZD-Z)使用的已发布指南,老年人应避免使用催眠性 BZD,并仅在低剂量和短时间内使用抗焦虑性 BZD 和 Z 类催眠药。我们的目的是量化老年人中不适当的 BZD-Z 使用情况。
研究人群包括年龄在 70-89 岁之间的人,他们在 2008 年期间在三个亚组中的至少两个亚组中至少开了两次处方:抗焦虑性 BZD、催眠性 BZD 或 Z 类催眠药。本研究使用的不适当使用标准为:(1)任何催眠性 BZD,(2)超过 300 DDD,或剂量超过 9 DDD/周,或抗焦虑性 BZD 和 Z 类催眠药使用超过 30 周。
118526 人,或 25%的挪威老年人,至少开了两次这些药物亚组中的一种药物的处方。25%的抗焦虑性 BZD 使用者、100%的催眠性 BZD 使用者和 65%的 Z 类催眠药使用者被发现使用不当。共有 57276 名挪威老年人,或 12.3%的老年人群,按照本研究的定义,不恰当地使用了 BZD-Z。
显然,BZD-Z 的不适当使用非常普遍。对这种不遵守现有指南的行为的积极应对措施可以包括:(1)更严格地执行指南,或(2)通过重新审视风险、益处和治疗实践来修改指南。这两种选择的影响都进行了详细的讨论。